1100 – Quantitative comparison of breast cancer therapeutic modalities between 2018 and 2025: an ecological study

Authors

  • Marya Eduarda de Melo Camilo Mendanha Universidade Federal de Goiás – Goiânia (GO), Brazil.
  • Pedro Henrique Lessa de Oliveira Universidade Federal de Goiás – Goiânia (GO), Brazil.
  • Samella Soares Oliveira Medeiros Universidade Federal de Goiás – Goiânia (GO), Brazil.
  • Felipe Rodrigues Resende Universidade Federal de Goiás – Goiânia (GO), Brazil.
  • Ana Luiza Naujorks Zimmer Universidade Federal de Goiás – Goiânia (GO), Brazil.
  • Eloah Vieira dos Santos Universidade Federal de Goiás – Goiânia (GO), Brazil.
  • Giovana Vilas Boas do Prado Universidade Federal de Goiás – Goiânia (GO), Brazil.
  • Nayara Alves de Freitas Lemos Universidade Federal de Goiás – Goiânia (GO), Brazil.

DOI:

https://doi.org/10.29289/25945394V36S11100

Keywords:

breast neoplasms, drug therapy, radiotherapy, mastectomy

Abstract

Introduction: According to the World Health Organization (WHO), in 2022, approximately 2.3 million new cases and
670 thousand deaths from breast cancer (BC) were recorded among women worldwide. This elevated mortality rate indicates that not all patients have adequate access to optimal treatment, which depends on accurate BC diagnosis to differentiate among molecular subtypes and select appropriate therapy.
Method: An ecological time-series study using secondary epidemiological and morbidity data obtained from DATASUS
through the Oncology Panel. Information on therapeutic modalities related to BC in women treated within the Brazilian
Unified Health System (SUS) was collected for the 2018–2025 time period. Data were analyzed using descriptive statistics.
Results: Between 2018 and 2025, 432,564 BC treatments were recorded in the SUS, increasing from 43,966 (2018) to 63,431
(2023), stabilizing in 2024 (63,244), and declining in 2025 (46,685). Chemotherapy (CT) was the predominant therapeutic modality (267,795), rising until 2024 (39,870) and decreasing in 2025 (25,935). Surgeries totaled 53,588, peaking in 2019
(8,993) and declining to 2,000 by 2025. Radiotherapy accounted for 23,468 procedures, with slight variation and a final
decrease (1,994 in 2025). Cases with missing information increased from 4,121 to 16,674, totaling 87,057.
Conclusion: There was an increasing trend in the total number of BC treatments in the SUS from 2018 to 2023, followed
by stabilization in 2024 and a marked reduction in 2025. The predominance of CT highlights its central role in systemic
management, while the reduction in surgeries may be associated with greater adoption of neoadjuvant treatment and a
preference for less invasive approaches. Therefore, improving data collection and integration in health information systems, as well as policies ensuring equitable and continuous access to therapeutic modalities, is essential.
Ethics: Public data.

Downloads

Download data is not yet available.

Downloads

Published

2026-10-19

How to Cite

Mendanha, M. E. de M. C., de Oliveira, P. H. L., Medeiros, S. S. O., Resende, F. R., Zimmer, A. L. N., dos Santos, E. V., … Lemos, N. A. de F. (2026). 1100 – Quantitative comparison of breast cancer therapeutic modalities between 2018 and 2025: an ecological study. Mastology, 36(suppl. 1). https://doi.org/10.29289/25945394V36S11100

Issue

Vol. 36 No. suppl. 1 (2026)

Section

Epidemiology Section

License

Copyright (c) 2026 Marya Eduarda de Melo Camilo Mendanha, Pedro Henrique Lessa de Oliveira, Samella Soares Oliveira Medeiros, Felipe Rodrigues Resende, Ana Luiza Naujorks Zimmer, Eloah Vieira dos Santos, Giovana Vilas Boas do Prado, Nayara Alves de Freitas Lemos

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.